GET DAILY SIGNALSCreative Medical Technology Holdings (CELZ): Can It Reach the $1 Level for a +61% Gain?
Key Takeaways
- The $1.00 central target used here is a fallback price objective tied to the Nasdaq minimum-bid listing threshold and the whole-dollar psychological level, not an analyst consensus. At about $0.62, reaching it requires a roughly 61% gain.
- Only one credentialed analyst price target exists: Roth MKM's Jonathan Aschoff reiterated a Buy rating and $20 target in July 2026. That implies roughly +3,100% upside and is treated as context, not as the central target.
- The stock is a micro-cap biotech with near-zero revenue, a trailing-twelve-month net loss near $6 million, and a 52-week range of roughly $0.59 to $4.72, putting it near its low.
- The strongest supports are positive interim data from the ADAPT chronic lower-back-pain trial and a new U.S. patent allowance covering Type 1 diabetes technology.
- The biggest risks are a critical dilution and warrant overhang, a short cash runway, and the risk of Nasdaq delisting if the shares stay below $1.
- For more context, explore Major News, Today's Price Move, the Forecast, and Earnings pages for this ticker.
- To broaden your research, explore Trending AI Robots for automated market analysis across stocks and ETFs.
Setting the $1 Price Objective
Creative Medical Technology Holdings, Inc. (CELZ) is a Phoenix, Arizona-based regenerative-medicine and immunotherapy biotechnology company. With essentially one active analyst target rather than a multi-analyst consensus, the headline $1.00 figure serves as a fallback objective drawn from public market discussion rather than an average of multiple targets. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
For context, Roth MKM analyst Jonathan Aschoff has maintained a Buy rating with a $20 price target on the shares, most recently reiterated in July 2026. That single target is the only credentialed analyst price target widely reported, and it implies an extreme, roughly +3,100% move that is unrealistically distant for a near-term objective. Separately, MarketBeat shows a mixed picture with no published consensus price target and a "sell"-leaning rating, underscoring how little institutional coverage this name actually has.
The $1.00 level stands out as a realistic, widely discussed milestone because Nasdaq Capital Market listings must generally maintain a $1.00 minimum bid price. With the stock trading near $0.62, regaining and holding $1 is the threshold most relevant to the company's listing status and to investor psychology.
Current Market Position and Path to the Target
The latest verified price is about $0.62 per share, near the low end of a 52-week range of roughly $0.59 to $4.72. Moving to $1.00 requires an approximately 61% gain, a very large move in percentage terms, even though the stock has produced even sharper single-session swings during 2026.
The path toward $1 would most plausibly run through a stabilization of the capital structure, additional positive clinical data, and a reduction in the dilution overhang that has pressured the shares. The company has a commercial-stage footprint through products such as CaverStem and FemCelz, but it generated only about $3,000 in trailing revenue and remains a clinical-stage operation in practice.
Factors That Could Support a Move Toward the Target
- Clinical momentum: The company completed enrollment in the FDA-cleared ADAPT trial for Olastrocel (CELZ-201-DDT) in chronic lower-back pain, and interim 180-day data showed a mean improvement of roughly 15 percentage points on the Oswestry Disability Index, with about 79% of patients achieving clinically meaningful functional improvement.
- Intellectual property: A U.S. patent allowance announced in August 2026 covers exosome-based immunotherapy for Type 1 diabetes, strengthening the MyeloCelz platform.
- Liquidity: The company reported roughly $8.8 million in cash in its most recent quarter, supplemented by warrant-exercise proceeds, which supports near-term operations.
- Large addressable markets: Type 1 diabetes alone represents a multibillion-dollar opportunity with substantial unmet need.
Risks That Could Prevent Reaching the Target
- Dilution overhang: Shareholders approved a 400% increase in authorized shares and the full exercise of warrants, leaving a warrant overhang of more than 200% of shares outstanding. Dilution-monitoring services flag this as a critical risk.
- Cash runway: With near-zero revenue and persistent operating losses, the company's runway has been estimated at roughly seven months, creating recurring financing pressure.
- Listing risk: A sustained sub-$1 price risks Nasdaq non-compliance, which could trigger a reverse split or delisting, both of which can further erode shareholder value.
- Clinical and regulatory uncertainty: A pivot toward a BLA (Biologics License Application) pathway raises research-and-development intensity and dependence on successful late-stage trials.
Technical Levels and Market Structure
The $0.59 area represents the 52-week low and near-term support. The $1.00 level is the primary psychological and regulatory resistance, with additional resistance near $1.60, where warrants were exercised, and higher prior trading levels around $1.97 and $2.86. The 52-week high near $4.72 marks the upper end of the recent range.
Time Horizon and Key Items to Watch
Most analyst price targets, including the single $20 Roth MKM target, are typically framed around a roughly 12-month horizon, though no formal horizon is published for this name. Investors should watch quarterly cash and burn figures, any new financing or warrant-exercise announcements, ADAPT trial readouts, Type 1 diabetes program updates, and whether the shares can regain and hold the $1.00 Nasdaq minimum-bid threshold. A reverse-split or delisting notice would be a material event to monitor.
AI Daily Buy/Sell Signals
For traders tracking volatile micro-cap names like this one, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. The tool is designed to help users discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening. Explore the signals to see how AI-driven analysis currently reads the risk and momentum in your watchlist.
Final Assessment
Can CELZ reach $1? The question is really about whether the shares can climb roughly 61% from their current level near $0.62, a move that is very large in percentage terms but modest relative to the stock's history of violent swings. The strongest case rests on positive interim ADAPT data and expanding intellectual property, while the principal obstacles are a severe dilution overhang, a short cash runway, and Nasdaq listing risk. With effectively one analyst target at $20 and a mixed "sell"-leaning view elsewhere, there is no meaningful analyst consensus to lean on. Regaining and holding the $1.00 minimum-bid level remains the single most important near-term milestone to watch.
Exploring Tickeron AI Tools
In my own research process, I often turn to Tickeron’s AI Trading Bots to test automated strategies on names like this and see how different market conditions might play out. It helps me stay objective when evaluating high-volatility micro-caps without relying solely on manual charts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Momentum Indicator for CELZ turns negative, indicating new downward trend
CELZ saw its Momentum Indicator move below the 0 level on October 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 99 similar instances where the indicator turned negative. In 91 of the 99 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CELZ turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 33 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for CELZ entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CELZ's RSI Oscillator exited the oversold zone, 28 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +12.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where CELZ advanced for three days, in 197 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
CELZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.546) is normal, around the industry mean (3.498). P/E Ratio (-0.303) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (833.333) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. CELZ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CELZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement